Document:

Amendment to Manufacturing and Supply Agreement

 Exhibit 10.25 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406. 

AMENDMENT TO MANUFACTURING & SUPPLY 
 AGREEMENT 
 This Agreement is made the 4th day of March 2011 (“Amendment Date”)
and is an amendment to the Manufacturing and Supply Agreement originally effective as of 3 August 2007 as that agreement has been amended from time to time (“Original MSA”) entered into between Horizon Pharma AG (previously
Nitec Pharma AG), a Swiss corporation having a place of business at Kägenstrasse 17, CH-4153 Reinach, Switzerland (hereinafter referred to as “Horizon”) and Jagotec AG, a Swiss corporation now having a place of business at
Eptingerstrasse 61, CH-4132 Muttenz, Switzerland (hereinafter referred to as “Jagotec”; Horizon and Jagotec hereinafter sometimes referred to as “Party” or “Parties”). 

Now, therefore, for and in consideration of the premises, mutual covenants and agreements contained herein and intending to be legally bound hereby the
Parties hereby agree as follows: 
  

	1.	For purposes of this Amendment Agreement, the terms defined in Article 1 of the Original MSA have the same meanings when used in this Amendment Agreement unless
specifically indicated otherwise. All references in the Original MSA to “Nitec” shall be deemed to be references to “Horizon”. 

  

	2.	Clause 1.28 of the Original MSA which reads: 

 ““Quality Agreement” shall mean the agreement dated as of the Effective Date on cGMP which agreement shall be attached hereto as Annex 5.” 

shall be deleted and replaced with the following: 

““Quality Agreement” shall mean the agreement between the Parties dated 4th March 2011 on cGMP which shall become effective on the
Amendment Date.” 
  

	3.	Clause 3.1 of the Original MSA which reads: 

Shall be deleted and replaced with the following: 
 Europe 

  
 1 

 “JAGOTEC shall manufacture the Product for marketing and sale by HORIZON in the Manufacturing Site in
strict compliance with the Specifications and the approved Manufacturing Process and in accordance with the Quality Agreement. Furthermore, JAGOTEC shall only use such equipment and personnel which are appropriate or duly qualified for the
manufacturing of Product in accordance with the provisions of this Agreement and the Quality Agreement. 
 Territory Outside Europe 

It is acknowledged and agreed between the Parties that in the course of obtaining Regulatory Approval to market and sell the Product in certain parts of
the Territory outside Europe it is possible that the Regulatory Authorities in such part of the Territory may require adjustments or amendments to the Specification and/or Manufacturing Process. In such an event the Parties will discuss in good
faith what changes to the Specifications and Manufacturing Process may be required to meet such adjustments or amendments and whether they can be achieved practically and economically and what impact this would have on pricing. Unless and until such
adjustments or amendments are agreed and come into force this Agreement (and for the avoidance of doubt the DLA) shall continue in full force and effect in accordance with its terms at the time. 

Clause 6.1. The fourth sentence of this clause in the Original MSA which reads: 
 “Jagotec shall provide to Nitec, at the beginning of each quarter for the following eight quarters with a capacity plan for the Product (“Capacity Plan”).” 

shall be amended by deleting such sentence and replacing it with the following: 

“Jagotec shall provide to Horizon at the end of each quarter in respect of the eight quarters immediately following such quarter, a
capacity plan for the Product (“Capacity Plan”).” 
  

	4.	Clause 6.2. The following wording at the beginning of this clause in the Original MSA which reads: 

  
 2 

 “NITEC shall issue for the first time on the date of signature hereof, and thereafter
during the term of this Agreement at the beginning of each quarter in accordance with Section 6.3, a rolling forecast (“Forecast”) for the upcoming [...***...]....” 

shall be amended by deleting the above wording and replacing it with the following: 

“Horizon shall issue, for the first time on the date of signature hereof, and thereafter during the term of this
Agreement at the end of each quarter in accordance with this Clause 6.2, a rolling forecast (“Forecast”) for the immediately following [...***...]...”. 

 

	5.	Clause 6.3. The first sentence of this clause in the Original MSA which reads: 

 “Any purchase order (to be sent out by NITEC on a monthly basis) shall be confirmed by JAGOTEC within 5 working days and shall be binding upon JAGOTEC, provided that the requested Delivery Day is not
earlier than [...***...] after the receipt of such purchase order and provided that such order shall correspond with the binding element of the Forecast for the month in question.” 

shall be amended by deleting such wording and replacing it with the following: 

“Any purchase order (to be sent out by Horizon on a monthly basis) shall be confirmed by Jagotec within five (5) working days
and shall be binding upon Jagotec provided that the requested Delivery Day is not earlier than at total of [...***...] plus [...***...], after receipt of such purchase order and provided that such order shall correspond with the
binding element of the Forecast for the month in question.” 
  

	6.	Clause 6.4 of the Original MSA shall be renumbered 6.4(a) and a new sub-clause 6.4(b) shall be added as follows: 

 

	 	b.	Horizon may from time to time propose to Jagotec “Manufacturing Dates” (which is defined as the day when the Active Ingredient comes into contact with the
excipients) in connection with the Forecasts under 6.2 and associated purchase orders under 6.3. The Parties shall discuss in good faith whether it is practical and economical to meet such Manufacturing Dates and if the Parties reach agreement and
confirm the same in writing by way of a revised confirmed purchase order Jagotec will use its commercially reasonable best efforts to meet the proposed Manufacturing Dates. 

 

	7.	Clause 7.2. Sub clause (a) of Clause 7.2 of the Original MSA which reads: 

 
 ***Confidential Treatment Requested 

  
 3 

	 	“(a)	Adjustments to Manufacturing Costs shall be calculated on the basis of [...***...] of the increase or decrease of the French Index of the Salaries of the
Pharmaceutical Industry;” 

 shall be deleted and replaced with the following: 

 

	 	“(a)	 Adjustments to the Manufacturing Costs shall be calculated on the basis of [...***...] of the increase or decrease of the
Ensemble Index as reported in the publication “Les Echos” (“Index”) over the Contract Year which includes the month of October when the adjustment takes place. If the Index fails or ceases to be published the Parties shall agree
a replacement index which is as similar as possible to the Index or in the absence of the parties reaching agreement on the same within 10 Business Days of a request by either Party such index as may be specified (on reference by either Party) by
the President of the Chamber de commerce et d’industrie, Lyon. 

 and in addition, the reference to
“Annex 3” in the penultimate line of Section 7.2 shall be amended to “Annex 4”. 
  

	8.	Clause 15.3 of the Original MSA shall be amended by changing the reference in respect of Jagotec AG from Eptingerstrasse 51 to Eptingerstrasse 61 and deleting the
reference to “Francesco Patalano” and inserting “General Counsel”. 

  

	9.	Clause 6.1 and Annex 9. For the avoidance of doubt, the Committee Members on the Parties at the Amendment Date are: 

In respect of Jagotec: Jean-Marc Chevalier (Directeur de Site) and Werner Enz (Vice President Commercial) 

And in respect of Horizon: Hans-Peter Zobel (VP Technical Operations & Development) and Joseph Whalen (VP, Business Development
and Licensing). 
  

	10.	The current Annex 2 of the Original MSA shall be deleted and replaced with the new Annex 2 attached to this Amendment Agreement. 

 

	11.	The current Annex 4 of the Original MSA shall be replaced with the new Annex 4 attached to this Amendment Agreement. 

 

	12.	The current Annex 5 of the Original MSA which reads: 

 “A Quality Agreement will be signed at the latest after manufacturing of the first campaign of the Product.” 
 shall be deleted and replaced with: 
  
 ***Confidential Treatment Requested 

  
 4 

 “A Quality Agreement will be agreed between the parties and have an effective date of
March 4, 2011.” 
 In all other respects, the terms of the Original MSA shall remain in full force and effect. 

IN WITNESS WHEREOF, the Parties have executed this Amendment Agreement effective 
 as of the “fourth day of March 2011”. 
 For an on behalf of JAGOTEC AG 

  

											
	 /s/ Axel Müller
	 	 	 	 /s/ Susan Ferguson
	 	 
	by:	 	Axel Müller	 		 	     by:	 	Susan Ferguson	 	
		 	CEO	 		 		 	Director	 	

 For an on behalf of HORIZON PHARMA AG 

 

											
	 /s/ Robert W. Metz 3/4/11
	 	 	 	 /s/ Hans-Peter Zobel 08.03.2011
	 	 
	by:	 	Robert W. Metz	 		 	     by:	 	Hans-Peter Zobel	 	
	 	 	Managing Director	 	 	 	 	 	Managing Director	 	 

  
 5 

 Annex 2 
 SPECIFICATIONS 
 (Final drug product release specifications)

 [...***...] 

(Acceptance Criteria for Hardness and Drug Release are defined below) 

 
 ***Confidential Treatment Requested 

  
 6 

 Acceptance Table for HARDNESS 

 

					
	 Test level
	 	 No. of units
	  	 Acceptance Criteria

			
	 T1
	 	 [...***...]
	  	 [...***...]

			
	 T2
	 	 [...***...]
	  	 [...***...]

			
	 T3
	 	 [...***...]
	  	 [...***...]

 Acceptance Table for DRUG RELEASE 
  

					
	 Stage
	 	 No. of units
	  	 Acceptance Criteria

			
	 S1
	 	 [...***...]
	  	 [...***...]

			
	 S2
	 	 [...***...]
	  	 [...***...]

[...***...]

			
	 S3
	 	 [...***...]
	  	 [...***...]

[...***...]

 
 ***Confidential Treatment Requested 

  
 7 

 Annex 4 
 PRICES 
 The following prices relate to the Packaged Product delivered Ex Works by
Jagotec: 
  

			
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	[...***...]	  	
		
	[...***...]	  	

 Payment shall be made in Euros by bank transfer within [...***...] of the invoice date, unless otherwise
agreed between the Parties. Bank transfer shall be made to such account as Jagotec shall notify to Horizon. 
  

***Confidential Treatment Requested 

  
 8Sales Contact

 Exhibit 10.29 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406. 

DATE: July 1, 2010 

Sales Contract 
 BASF Corporation, with
offices at 100 Campus Drive, Florham Park, New Jersey 07932 (“Seller”) hereby agrees to sell Product to: Horizon Pharma USA, Inc. (“Buyer”), with offices at 1033 Skokie Boulevard, Suite 355, Northbrook, Illinois, 60062, and Buyer
hereby agrees to purchase Product from Seller for shipment to locations designated by Buyer in USA, Canada or the European Union according to the following terms and conditions: 
 DISTRIBUTION CHANNEL: In reference to the existing Distributor Agreement between BASF and Ceres Chemical Co., Inc. (“Ceres”), Seller and Buyer agree that the Buyer or the Buyer’s
dedicated representative has to purchase the Product in accordance with the terms and conditions of this Contract in so far as applicable, from Ceres until the expiry of the Distributor Agreement with effect as of [...***...]. Thereafter the
sale/purchase transactions will be conducted directly between the Seller and the Buyer or the Buyer’s dedicated representative in accordance with the terms and conditions of this Contract. 

TERM: Effective on the last signature date and through December 31, 2017 (the “Initial Term”), whereby the term shall automatically
renew for successive renewal terms of [...***...] years each, unless either party gives written notice of non-renewal at least [...***...] days prior to the end of the Initial Term or any successive [...***...]-year renewal term,
in which case this Agreement shall automatically expire at the end of such Initial Term or renewal term, as applicable. In the event the Buyer does not secure regulatory approval of Horizon’s HZT-501 product in the United States by
December 31, 2011, then this Contract shall automatically terminate, and the Buyer will pay Seller a termination fee in accordance with the terms of this paragraph. Within 30 days following the date of signature of this Contract, the Buyer will
pay Seller [...***...] as pre-purchase credit (the “pre-purchase credit”) to be used exclusively as Buyer’s payment against the first [...***...] purchased between [...***...] and for no other purpose, except as
otherwise expressly set forth below. In the event this Contract terminates due to failure of Buyer to secure regulatory approval of Horizon’s HZT-501 product in the United States by December 31, 2011, the termination fee therefore as set
forth above shall be equal to the amount, if any, remaining of the pre-purchase credit as of December 31, 2011, and Seller’s retention of such amount, if any, shall be deemed Buyer’s payment and full satisfaction thereof. In the event
that the Contract is not terminated prior to [...***...], and the Buyer purchases less than [...***...] of Product between [...***...], then Seller will withhold from such pre-purchase credit a prorated good will fee from Buyer
that is calculated in the following manner (provided, however, that in no event shall such good will fee exceed the amount, if any, remaining of the pre-purchase credit as of [...***...], and any amount of the pre-purchase credit remaining
after Seller’s withholding of the prorated good will fee will be promptly returned to Buyer): 
 [...***...] multiplied by a fraction
equal to (a) [...***...] minus the actual volume of Product in (MTs) purchased, divided by (b) [...***...]. Example, Seller purchases [...***...] MT of Product in this [...***...] years, then Seller will withhold
from Buyer [...***...]. In the event that Buyer has not purchased [...***...]MT during this [...***...] years, Buyer reserves the option to purchase the outstanding quantity of material sufficient to satisfy the volume requirement
at the then going rate. In the event BASF can not deliver the Product, then, the shortage volume will be deducted from this [...***...] MTs. 
 PRODUCT: Ibuprofen DC85 that conforms to the Specifications 
 SPECIFICATIONS:
Attached as Exhibit 1 
 QUANTITY: Buyer agrees to purchase minimum [...***...] of its commercial demand for Product from Seller up
to a maximum of [...***...] MT/year. If Buyer desires to purchase Product in a quantity in excess of [...***...] MT/year, Buyer will notify Seller and the parties will discuss in good faith the purchase of such additional quantity from
Seller subject to mutual written agreement on terms. 
 VOLUME LIMITATION: During each calendar month during the Term, Buyer shall
purchase and receive no less than [...***...] of 1/12th of the annual quantity estimate of Product set forth herein, and Seller shall be obligated to sell and deliver no more than [...***...] of 1/12th of such annual quantity estimate of
Product. If no estimated quantity is set forth herein, it is intended that Buyer will order Product in approximately level quantities over the Term, subject to normal seasonal fluctuations that Seller has accepted in writing. 

If Buyer purchases less than the above-stated minimum quantity of Product during any calendar month (for reasons other than those excused under
Section 4 of the General Terms and Conditions of Sale attached hereto), Seller may, without limiting any other legal remedies that may be available to Seller, reduce the quantity of Product Seller is obligated to supply during each succeeding
calendar month of the Term to an amount equal to [...***...] of such lesser quantity, and if Seller does so, then the minimum quantity of Product required to be purchased by Buyer in each succeeding calendar month of the Term shall be
commensurately reduced. 
 PRICE: From [...***...] the price will be [...***...]/kg plus adjustment based on Pharmaceutical
Production (PPI) index (pcu325412325412) (http://data.bls.gov/PDQ/servlet/SurveyOutputServlet?series_id=PCU325412325412&data_tool=XGtable) for pharmaceutical preparation manufacturing as defined by the US Bureau of Labor Statistics of the
prior calendar year which becomes effective January 1, 2011. With adjustment occurs only once per calendar year effective at [...***...]. 
 Formula [...***...] X PPI (actual) / PPI (base) 
 PPI (actual) = PPI annual average index
for the prior calendar year (two parties agree to use published preliminary data for the last 4 months) 
 ***Confidential
Treatment Requested 

  

 PPI (base) = PPI annual average index for 2011 calendar year 

For example, PPI (base) = 480, PPI (actual 2013) = 490 based on actual average index of 2012 
 Price for 2013 = [...***...]/kg x 490 / 480 = [...***...]/kg 
 TERMS OF
PAYMENT: Net cash within [...***...] days from the later of the date of shipment or receipt of the applicable invoice, unless such shipment of Product is rejected in accordance with the provisions of Section 6 of the attached Terms,
unless other determined with Ceres for the period through February 1, 2013. 
 PACKAGING: [...***...] kg 

DELIVERY TERMS: FCA (Incoterms 2000) Seller’s facility in New Jersey, or Welch’s facility in Michigan, or Dr. Reddy’s facility
in Louisiana 
  

	SHIPMENT:	As ordered by Buyer in approximately equal monthly quantities, unless otherwise stated in the following shipping schedule, during the Term. 

 

	QUALITY:	Terms in Quality Agreement between Buyer and Seller will prevail for all quality and regulatory related issues. 

SHIPPING SCHEDULE: 
 FORECAST: Prior to
September 30 of each year of this Agreement, Buyer shall submit to Seller a forecast of quantities of Product Buyer intends to order from Seller during the following calendar year. Buyer shall update the forecast for the following calendar year
on a monthly basis (capacity-planning quantities). Attached as Exhibit 2 is Buyer’s initial non-binding forecast. Firm and binding orders shall be submitted to Seller at least [...***...] prior to the required delivery dates 

 

	TERMS AND CONDITIONS:	THE BASF GENERAL TERMS AND CONDITIONS OF SALE ATTACHED HERETO ARE HEREBY INCORPORATED IN AND MADE A PART OF THIS CONTRACT. 

[Signatures next page] 
 ***Confidential Treatment Requested 
  

 2 

 This Contract is not valid unless countersigned by BASF. 

ACCEPTED: 
  

									
	Horizon Pharma USA, Inc. (Buyer)	 		 	BASF                 (Seller)
					
	By:	 	/s/    TIMOTHY P. WALBERT	 		 	By:	 	/s/    SIMON D. MEDLEY
					
	Title:	 	Chairman, President & CEO	 		 	Title:	 	Group Vice President care chemicals
					
	Date:	 	July 19, 2010	 		 	Date:	 	July
16th, 2010

  

 Exhibit 1. Ibuprofen DC85 Specification 

 

					
	 Test
	  	 Method
	  	Acceptance Criteria
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]
			
	 [...***...]
	  	[...***...]	  	[...***...]

***Confidential Treatment Requested 
  

 4 

 [...***...] 
  

															
	  	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

***Confidential Treatment Requested 
  

 5 

 BASF - GENERAL TERMS AND CONDITIONS OF SALE 

(as amended for Horizon Pharma USA, Inc.) 
 1. Entire Agreement. These Terms and Conditions of Sale (the “Terms”), together with other sales terms, if any, agreed to by Buyer and Seller in a writing (“Sales
Terms”), contain the entire and exclusive agreement between the parties regarding the sale of each Product. The Terms, together with the Sales Terms, if any, are referred to herein as the “Contract”. If there is a conflict between the
Terms and the Sales Terms, the Sales Terms shall govern. All terms and conditions contained in any prior or subsequent oral or written communication, including, without limitation, terms and conditions contained in Buyer’s purchase order, which
are different from or in addition to the Contract are hereby rejected and shall not be binding on Seller or Buyer, and Seller hereby objects thereto, unless expressly agreed in writing to be an amendment to the Contract and signed by both Buyer and
Seller. No addition to, or alteration or modification of, the Contract shall be valid unless made in a writing signed by an authorized representative of each party specifically referring to the Contract. Buyer and seller both agree that the current
confidentiality agreement between the parties covers any disclosures under this agreement 
 2. Payment; Taxes. The price
for Product is the price in effect on the date of shipment, unless otherwise agreed by the parties. Seller may adjust the price of any Product subject to the terms outlined in the Price section of the Sales Terms. Payment for the full amount of each
invoice shall be made to Seller, addressed as indicated on an invoice, in United States currency. All claims by Buyer shall be made by written notice to Seller in accordance with the provisions of Section 6 of these Terms, and no offset or
deduction from any invoice is permitted. Acceptance by Seller of bank draft, check, or other media of payment is subject to immediate collection of the full face amount thereof. 

In addition to the purchase price, Buyer shall pay Seller any and all governmental taxes, charges or duties of every kind (excluding any
tax based upon Seller’s net income or net worth) that Seller may be required to collect or pay upon sale, transfer or shipment of Product (“Tax”). Notwithstanding the above, Seller shall not collect, and Buyer shall not pay, any such
Tax for which Buyer furnishes to Seller a properly completed exemption certificate or a direct payment permit certificate. Buyer shall be responsible for any Tax, interest and penalty, if such exemption certificate or direct payment permit
certificate is disallowed by the proper taxing authority. 
 3. Breach; Termination. If Buyer breaches any term of the
Contract, (a) Seller may choose to defer any or all further shipments or other performance under the Contract until Buyer cures its breach, or (b) Seller may immediately terminate the Contract if Buyer fails to cure such breach within
[...***...] after receipt of written notice from Seller describing such breach. If Seller breaches any term of the Contract, Buyer may immediately terminate the Contract if Seller fails to cure such breach within [...***...] after
receipt of written notice from Buyer describing such breach. In the event of a termination, all outstanding payment obligations or other indebtedness of Buyer to Seller shall be due and payable no later than [...***...] after delivery of
notice of termination. Acceptance by Seller of less than the full amount due or termination of the Contract by either party shall not be a waiver of any rights of either party under the Contract or applicable law. 

Notwithstanding any provision in the Contract, Seller shall have no obligation to pay any rebate, issue any credit or make any other
payment of any kind to Buyer unless Buyer is fully in compliance with its payment and other obligations under the Contract and any other contractual obligation in favor of Seller. In addition, in the event that Buyer fails to make any payment when
due, Seller shall have the right to offset any and all outstanding payment obligations or other indebtedness of Buyer to Seller against any outstanding payment obligations or other indebtedness that Seller or any of its affiliates may owe Buyer.

 4. Force Majeure. Neither Seller nor Buyer shall be responsible for any delay or failure to make or take delivery of
Product due to any cause beyond its reasonable control, including without limitation (a) fire, storm, flood, strike, lockout, accident, act of war or terrorism, riot, civil commotion, embargo, (b) any regulation, law, order or restriction
of any governmental department, commission, board, bureau, agency, court, or other similar government instrumentality (“Governmental Authority”), or (c) inability of Seller to obtain any required raw material, energy source,
equipment, labor or transportation, at prices and on terms Seller deems practicable from Seller’s usual sources of supply. Neither party is subject to any liability to the other for failing to perform during the period such inability exists.
Without limiting the generality of the foregoing, under no circumstances shall Seller be obligated to purchase Product from a third party for delivery to Buyer in the event of a force majeure. Quantities so affected may, at the option of either
party, be eliminated from the Contract without liability, but the Contract shall remain otherwise unaffected. 
 5. Compliance with
Laws. Seller shall provide or make available to Buyer a Material Safety Data Sheet (MSDS) for each Product. The MSDS contains Product information and describes precautions, if required, associated with such things as transportation,
delivery, unloading, discharge, storage, handling and use of the Product. Buyer will familiarize itself with all such information and precautions, including but not limited to safety and health information contained in MSDSs or otherwise transmitted
to Buyer by Seller at any time. Buyer will instruct its personnel, agents, contractors, customers or any third party who may be exposed to the Product about such information and precautions, and make copies available to such parties. Buyer assumes
full liability and responsibility for compliance with the MSDS. In addition, in connection with this Contract, each of Seller and Buyer shall comply with all applicable laws, statutes, ordinances and regulations of any Governmental Authority
including, without limitation, the Foreign Corrupt Practices Act, the anti-money laundering provisions of the USA Patriot Act and Bank Secrecy Act, and United States export control laws (“Applicable Laws”). Buyer shall not resell or ship
any Product to persons on the Denied Parties List or persons located within embargoed countries (in both cases as defined under the referenced export control laws). Seller assumes no liability for Buyer’s failure to comply with Buyer’s
obligations arising under European Union REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) Regulations. Buyer shall defend, indemnify and hold harmless Seller from and against all damages, losses, liabilities, costs,
expenses (including reasonable attorneys’ fees), penalties, and judgments incurred by Seller as a result of any third party claims, demands or causes of action (each, a “Claim”) arising out of or related to (i) Buyer’s (or
others’) processing, transportation, delivery, unloading, discharge, storage, handling, sale or use of any Product (or any product containing Product) or (ii) Buyer’s violation of any Applicable Laws, except, in each case, to the
extent such losses result from the breach of this Agreement by, or the negligence or willful misconduct of, Seller or any party acting on behalf of Seller hereunder. Seller assumes no liability for failure of discharge implements or unloading
equipment used by Buyer, whether or not supplied by Seller. 
 6. Warranties. SELLER WARRANTS THAT AT THE TIME OF DELIVERY
(I) PRODUCT IS FREE AND CLEAR OF ALL LIENS, ENCUMBRANCES AND SECURITY INTERESTS; AND (II) PRODUCT COMPLIES WITH SELLER’S PUBLISHED SPECIFICATIONS (OR AS OTHERWISE REFERENCED IN THE CONTRACT). SELLER MAKES NO OTHER WARRANTY OR GUARANTEE OF
ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE OR MERCHANTABILITY. 
  

 ***Confidential Treatment Requested 

1. 

 BUYER SHALL INSPECT THE PRODUCT SUPPLIED HEREUNDER IMMEDIATELY AFTER DELIVERY.
EXCEPT WITH RESPECT TO CLAIMS FOR SHORTAGES[ OR FOR LATENT DEFECTS (AS PROVIDED BELOW)], BUYER’S FAILURE TO GIVE NOTICE TO SELLER OF ANY CLAIM WITHIN [...***...] AFTER THE DATE OF
DELIVERY SHALL CONSTITUTE UNQUALIFIED ACCEPTANCE OF THE PRODUCT AND A WAIVER BY BUYER OF ALL CLAIMS WITH RESPECT THERETO. Buyer may reject any portion of any shipment of the Product that does not conform to the warranties set forth in the
Contract by giving notice to Seller of such claim within [...***...] after the date of delivery[; provided, however, that in the case of any Product having latent defects that could not have been discovered by Buyer within
[...***...] of delivery despite reasonable inspection by Buyer, Buyer may reject such Product by giving written notice to Seller of Buyer’s rejection of such Product within [...***...] after discovery of such latent defect(s), but
such notice may in no event be given later than [...***...] after receipt of such shipment]. Whether or not Seller accepts Buyer’s basis for rejection, Seller will supply replacement Products within [...***...] of notice of
rejection at no additional cost. Within [...***...] of receiving any notice of rejection from Buyer, Seller will respond stating whether (a) it accepts the rejection or (b) it disputes the rejection, in which case the parties will
refer such dispute to a mutually acceptable independent third party with the appropriate expertise to assess the conformity or non-conformity of the rejected Product. Such independent third party shall test the applicable Product and shall determine
whether such Products were conforming or non-conforming. The parties agree that such third party’s determination shall be final and binding upon the parties. The party against whom the independent third party rules shall bear the costs of
testing by such independent third party, and if such third party determines that Seller’s rejection of Product was incorrect, Seller will purchase and pay for both the initially rejected and replacement Products. 

CLAIMS FOR SHORTAGES MUST BE RECEIVED BY SELLER IN WRITING WITHIN [...***...] AFTER DELIVERY OF PRODUCTS. SELLER SHALL BE
GIVEN A REASONABLE OPPORTUNITY TO INSPECT ANY SHIPMENT CLAIMED BY BUYER TO CONTAIN A SHORTAGE. SELLER SHALL PROMPTLY DELIVER PRODUCT FOR ANY CLAIMED SHORTAGE WITHIN [...***...] AFTER WRITTEN NOTICE OF SUCH SHORTAGE BY SELLER, AT SELLERS
EXPENSE. 
 ANY TECHNICAL ADVICE FURNISHED OR RECOMMENDATION MADE BY SELLER OR ITS REPRESENTATIVE CONCERNING ANY USE OR
APPLICATION OF ANY PRODUCT IS BELIEVED TO BE RELIABLE BUT SELLER MAKES NO WARRANTY, EITHER EXPRESS OR IMPLIED, AS TO ITS ACCURACY OR COMPLETENESS OR OF THE RESULTS TO BE OBTAINED. WITH REGARD TO ANY HANDLING OF ANY PRODUCT, BUYER ASSUMES FULL
RESPONSIBILITY FOR QUALITY CONTROL, TESTING AND DETERMINATION OF SUITABILITY OF PRODUCT FOR ITS INTENDED APPLICATION OR USE. 
 7.
Intellectual Property. Seller warrants that the process or processes of manufacture of the Product and the Product itself do not infringe any U.S. patents and agrees to defend, indemnify and hold harmless Buyer from and against all
Claims arising out of or related to infringement of any U.S. patent by the practice or use of the process or processes of manufacture of the Product by Seller or the Product delivered by Seller. 

Since Seller has no control over Buyer’s (or others’) processing, sale, use, or disposition of any Product (or any product
containing Product), including, without limitation, the admixing, reacting or combining of any Product with other products, chemicals or materials, Buyer assumes the entire liability and responsibility therefor and agrees to defend, indemnify and
hold harmless Seller from and against all Claims arising out of or related to infringement of any third party’s patents, patents on processes practiced by Buyer or patents on products made by Buyer by the processing, sale, use, or disposition
of any Product (or any product containing Product), including, without limitation, the admixing, reacting or combining of any Product with other products, chemicals or materials, by or on behalf of Buyer after purchase from Seller. 

8. Limitation of Liability. THE REMEDIES SET FORTH IN SECTION 6 ARE BUYER’S SOLE AND EXCLUSIVE REMEDY FOR ANY PRODUCT THAT DOES NOT
COMPLY WITH THE WARRANTIES SET FORTH IN SECTION 6. SELLER’S TOTAL LIABILITY AND BUYER’S EXCLUSIVE REMEDY FOR ANY CAUSE OF ACTION ASSOCIATED WITH THE CONTRACT, WHETHER BASED IN TORT, CONTRACT, STRICT LIABILITY OR ANY OTHER LEGAL THEORY
IS EXPRESSLY LIMITED TO PAYMENT IN AN AMOUNT [...***...], EXCEPT IN THE EVENT OF NEGLIGENCE OR WILLFUL MISCONDUCT BY SELLER. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY OTHER DAMAGES INCLUDING, WITHOUT LIMITATION, INCIDENTAL,
SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES. SUCH EXCLUDED INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES INCLUDE LOSS OF PROFITS, LOSS OF PRODUCTION, LOSS OF USE, OR ANY OTHER INDIRECT DAMAGE OR LOSS OF ANY KIND OR CHARACTER TO THE OTHER PARTY, ITS
CUSTOMERS, SUPPLIERS, OR OTHER PERSONS OR ENTITIES. ANY ATTEMPT BY BUYER TO REMEDY OR CORRECT A CLAIMED DEFECT BY PERSONS OR ENTITIES NOT AUTHORIZED TO PERFORM SUCH WORK BY SELLER OR CONTINUED USE OF SUCH PRODUCT SHALL VOID THE PRODUCT WARRANTY SET
FORTH IN SECTION 6(II) ABOVE AND BUYER IS DEEMED TO HAVE ACCEPTED THE PRODUCT AS IS, WITH NO FURTHER OBLIGATION OF SELLER TO BUYER. IF REQUESTED BY SELLER IN WRITING NO LATER THAN [...***...] AFTER THE DATE OF BUYER’S WRITTEN
NOTICE OF REJECTION, BUYER SHALL RETURN THE NONCONFORMING PRODUCT TO SELLER STRICTLY IN ACCORDANCE WITH SELLER’S WRITTEN INSTRUCTIONS CONCERNING SHIPPING, HANDLING, INSURANCE, AND OTHER MATTERS AS TO WHICH SELLER ISSUES INSTRUCTIONS, AT
SELLER’S EXPENSE. FAILURE TO COMPLY WITH THESE PROVISIONS SHALL INVALIDATE ANY CLAIM BY BUYER FOR BREACH OF WARRANTY. 
 9.
Limitation of Action. BUYER’S FAILURE TO COMMENCE ANY CAUSE OF ACTION RELATED TO THE PRODUCT OR OTHERWISE ARISING UNDER THE CONTRACT WITHIN ONE YEAR AFTER THE DATE OF DELIVERY SHALL CONSTITUTE A WAIVER BY BUYER OF ANY OTHERWISE
APPLICABLE STATUTE OF LIMITATIONS AND FOREVER BAR ALL RIGHTS TO COMMENCE ANY CAUSE OF ACTION WITH RESPECT THERETO. 
 10.
Allocation. Seller may allocate its available supply of Product among its customers, itself, and its affiliates on such basis as Seller deems fair and reasonable if Seller is unable, for any reason, to supply the quantities of Product
contemplated by the Contract. 
 11. Credit. If at any time the financial responsibility of Buyer, or the credit risk involved,
shall become unsatisfactory to Seller, Seller may require cash or satisfactory security prior to subsequent shipments or deliveries hereunder. The election by Seller to require such cash or security shall not affect the obligation of Buyer to take
and pay for the contracted Product. Buyer agrees to pay all costs and expenses, including reasonable attorneys’ fees, incurred by Seller in the collection of any sum payable by Buyer to Seller. Seller shall be entitled to interest on any
overdue sum at the maximum rate allowed by applicable law. 
 12. Title; Risk of Loss. Unless otherwise provided in the Contract
(e.g., an INCOTERM), risk of loss of Product shall transfer at Seller’s plant of manufacture. In addition, unless otherwise provided in the Contract, title to Product shall transfer to Buyer simultaneously with risk of loss. 

 

 ***Confidential Treatment Requested 

2. 

 13. Intentionally deleted. 
 14. Intentionally deleted. 
 15. Assignment; Survival. Neither party
shall assign all or any portion of the Contract without the other party’s prior written consent, which consent shall not be unreasonably withheld; provided, however, that either party may, without such consent, assign this Agreement, in whole
or in part, in connection with the transfer or sale of all or substantially all of the assets or business of such Party relating to the product(s) to which this Agreement relates. The Contract shall bind and inure to the benefit of the successors
and permitted assigns of the respective parties. Any assignment or transfer not in accordance with this Contract shall be void. In order that the parties may fully exercise their rights and perform their obligations arising under the Contract, any
provisions of the Contract that are required to ensure such exercise or performance (including any obligation accrued as of the termination date) shall survive the termination of the Contract. 

16. Governing Law; Miscellaneous. The Contract shall be governed by the laws of the State of Delaware, USA, excluding its conflict of laws
principles. The parties agree, consent and waive contest to the exclusive jurisdiction and venue of the federal or state courts of New Jersey for all disputes arising out of or relating to this Contract. The United Nations Convention on Contracts
for the International Sale of Goods and the United Nations Convention on the Limitation Period in the International Sale of Goods, as amended, shall not apply to the Contract. Failure of either party to exercise any right it has under the Contract
on one occasion shall not operate or be construed as a waiver by such party of its right to exercise the same right on another occasion or any other rights it has. Any waiver must be in a writing signed by the waiving party. If any provision of the
Contract shall be adjudicated to be invalid or unenforceable, it is the parties’ intent that the remaining provisions of the Contract will remain in full force and effect, and the affected provision or portion thereof will be deemed modified so
that it is enforceable to the maximum extent permissible to reflect as closely as possible the intentions of the parties as evidenced from the provisions of the Contract. The section headings used herein are intended for convenience of reference
only and shall not be considered in interpreting the Contract. Nothing in the Contract shall be construed as creating any direct or beneficial right in or on behalf of any third party. 
  

 3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}]]